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Background. Psoriasis is a chronic inﬂammatory skin disease characterized by an accelerated turnover of epidermal cells and an
incompletediﬀerentiationinepidermiswithlesion.However,theexactetiologyofpsoriasisisunknown.Abnormalitiesinessential
fatty acid metabolism, free radical generation, lipid peroxidation, and release of lymphokines have been proposed. Objective.O u r
purpose was to evaluate the plasma lipids and oxidized low-density lipoprotein accumulation in psoriatic skin lesion in order to
ascertain the possible participation of oxidative stress and oxidative modiﬁcation of lipids in pathogenesis of psoriasis. Methods.
The study group included 84 patients with psoriasis, and 40 sex- and age-matched healthy volunteers. Blood lipid proﬁle was
determined. Psoriatic and nonlesional skin samples of psoriatic patients were evaluated for the presence of oxidized low-density
lipoprotein by using an immune-ﬂuorescent staining method. Results. The mean levels of lipids (total cholesterol, triglyceride,
and LDL cholesterol) in patients with psoriasis were found to be signiﬁcantly higher than those of healthy subjects. Psoriatic
skins were shown positive oxidized low-density lipoprotein staining. There was no staining in nonlesional skin samples of the
same individuals. Conclusion. Lipid peroxidation mediated by free radicals is believed to be one of the important causes of cell
membrane destruction and cell damage. This study shows for the ﬁrst time the accumulation of oxidized low-density lipoprotein
in psoriatic skin lesion. We believe that accumulation of ox-LDL in psoriatic skin may have an important role in the immune-
inﬂammatory events that result in progressive skin damage.
Copyright © 2007 Nilgun Solak Tekin et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The etiology of psoriasis is unknown, but genetic, metabolic,
and immunologic mechanisms have been proposed [1]. It is
known that psoriasis can occur due to abnormalities in es-
sential fatty acid metabolism, lymphokine release, free radi-
cal generation, and lipid peroxidation. Alterations in plasma
lipid and lipoprotein composition including a tendency to-
ward an increase in total cholesterol (TC) and triglyceride
(TG) and decrease in high-density lipoprotein cholesterol
(HDL-C) levels suggest that psoriasis may associate with the
disorders of lipid metabolism [2, 3]. Healthy skin secretes
85mg of cholesterol within 24 hours whereas a psoriatic pa-
tient loses 1–2 grams of cholesterol with scales during that
time [1].
The morphology of psoriatic skin is characterized by
epidermal thickness and parakeratosis, a pronounced der-
mal vascular plexus, and the presence inﬂammatory cells in
the superﬁcial dermis and epidermis. Increased polymorph
nuclear leukocyte levels damage surrounding tissue by re-
leasing reactive oxygen species produced via NADPH ox-
idase/myeloperoxidase and proteolytic enzymes. Increased
production of oxygen metabolites is a common feature of
most human diseases including psoriasis and it usually trig-
gers an upregulation of the antioxidant capacity, which is
overwhelmed. When the oxidative stress develops, it leads to
the oxidative damage of lipids and proteins [2, 4, 5]. Oxi-
dation of the low-density lipoproteins (LDL) results in the
production of modiﬁed LDL. One of the major and early
lipid peroxidation products is oxidized low-density lipopro-
tein (ox-LDL) [6].
High titers of autoantibodies against ox-LDL have been
reported in patients with psoriasis. The level of autoantibod-
ies against ox-LDL has been suggested to reﬂect the in vivo
oxidation of LDL [7, 8]. The presence of ox-LDL accumula-
tion in psoriatic skin sample has not been shown before. The2 Mediators of Inﬂammation
current study has been designed to evaluate the presence of
ox-LDL accumulation in skin biopsy materials of psoriatic
patients. We have also measured plasma lipids.
2. MATERIALS AND METHODS
2.1. Studygroups
This prospective study was performed in the psoriatic pa-
tientsattendingthedermatologyoutpatientclinicofZongul-
dak Karaelmas University Hospital. Eighty four psoriatic pa-
tients who were diagnosed clinically and histopathologically
by the Department of Dermatology and a total of 40 age-
and sex-matched healthy controls recruited from the general
population as a control group were enrolled in the study. All
patients had apparent psoriatic lesions, but no erythroderma
or generalized pustulosis. They had not taken any medi-
cal treatment before. The patients with secondary hyper-
lipidemia such as chronic renal insuﬃciency, nephrotic syn-
drome, hypothyroidism, diabetes mellitus, obstructive liver
disease, and the connective tissue disease were excluded. All
patients and controls were included in the study after giving
an informed consent. The Ethics Committee of Zonguldak
Karaelmas University approved the study.
T h eh e i g h ta n dw e i g h to fa l ls u b j e c t sw e r er e c o r d e da n d
theirbodymassindexeswerecalculatedasweight(kg)/height
(m2).
2.2. Determinationoflipidsandlipoproteins
Blood samples were taken after a 12-hour overnight fast and
sera were separated by low-speed centrifugation for 15min.
The levels of serum TC, HDL-C, LDL cholesterol (LDL-C),
and TG were determined by enzymatic methods using a
Roche Cobas Integra 800 autoanalyzer.
2.3. Ox-LDLimmune-ﬂuorescentstainingmethodof
theskinbiopsymaterials
The skin punch biopsy specimens were collected from both
lesional and nonlesional skin of 84 psoriatic patients. Unin-
volved abdominal area was used as nonlesional skin sam-
ple. The presence of ox-LDL in biopsy materials of psori-
atic individuals was evaluated using an immune-ﬂuorescent
staining method. The slides were prepared from biopsy sec-
tions, which were cut at 7-micron thickness. Slides were
further divided into two pieces; one was used for the test
and the other was used for negative control. Thirty µl anti-
oxidized LDL IgG solution (mouse IgG2 antibodies, Anti-
bodyShop, Copenhagen, Denmark) as primary antibody was
added only on test slides, and the control slides were ma-
nipulated only with the same amount of phosphate buﬀered
saline solution (PBS). After 30 minutes of incubation in a
humid chamber at room temperature, both the control and
test slides were washed with (PBS), and 30µl FITC (ﬂuores-
cent isothiocyanate)-labeled goat anti-mouse IgG (Chemi-
con International, California, USA) was administered as a
Table 1: The clinical and demographic characteristics of the psori-
atic patients and the control group.
Patients Controls P
(n = 84) (n = 40)
Age (y) (median) (range) 39 (17–58) 36 (19–55) >. 05
Gender (M/F) 41/43 20/20 >. 05
Height (cm) 172 ±01 167.5 ±9.5 >. 05
Weight (kg) 75 ±03 70.7 ±12.0 >. 05
BMI (kg/m2) 25.2 ±5.12 5 .3 ±4.8 >. 05
BMI: body mass index.
Table 2: Plasma lipids and lipoproteins in patients with psoriasis
and control subjects.
Patient Control P
(n = 84) (n = 40)
TC (mg/dl) 183,51 ±13,19 169,45 ±24,02 .030∗
TG (mg/dl) 124,17 ±58,57 85,15 ±40,98 .001∗
LDL-C (mg/dl) 108,58 ±32,76 96,30 ±25,65 .031∗
HDL-C (mg/dl) 48,57 ±12,88 56,18 ±15,30 .005∗
∗Statistically signiﬁcant.
conjugatesubstance.Forafurther30minutes,theslideswere
kept and incubated at room temperature, and then washed
with the standard PBS solution. After open-air drying, slides
were examined under ﬂuorescent microscopy at 100X mag-
niﬁcation (LEICA DMRX, Wetzlar, Germany).
2.4. Statisticalanalysis
Data were expressed as the means and standard deviations
(SD). Diﬀerences in continuous variables between the pa-
tient and the control groups were analyzed using the Student
t-test. Mann-Whitney U test was used to compare nonpara-
metric variables between two groups. SPSS Windows release
11.5 was used. All values were expressed as mean ± stan-
dard deviation (SD) unless otherwise stated. Statistical sig-
niﬁcance level was set to .05 for all calculations.
3. RESULTS
Table 1 illustrates the clinical and demographic characteris-
tics of the study population. There was no statistically signif-
icant diﬀerence between psoriatic patients and the controls
considering age, sex, weight, height, or BMI (P>. 05).
The levels of the lipid parameters are shown in Table 2.
TC, TG, and LDL-C levels were signiﬁcantly higher, but
HDL-C levels were lower in the psoriatic patients than in the
control subjects. However, gender-related results were com-
pletely diﬀerent. HDL-C levels were signiﬁcantly lower in
the female psoriatic patients than in the female control sub-
jects (P<. 05). There was no statistically diﬀerence for TC,
TG, and LDL-C levels between the psoriatic and the control
subjects in the female group (Table 3). TC, TG, and LDL-CNilgun Solak Tekin et al. 3
Table 3: Plasma lipids and lipoproteins in patients with psoriasis
and control subjects for females.
Patient Control P
(n = 43) (n = 20)
TC (mg/dl) 179,27 ±43,72 166,55 ±23,43 .268
TG (mg/dl) 102,59 ±37,88 85,00 ±41,49 .075
LDL-C (mg/dl) 102,65 ±35,20 94,60 ±21,70 .457
HDL-C (mg/dl) 52,18 ±13,81 61,45 ±15,22 .021∗
∗Statistically signiﬁcant.
Table 4: Plasma lipids and lipoproteins in patients with psoriasis
and control subjects for males.
Patient Control P
(n = 41) (n = 20)
TC (mg/dl) 188,08 ±28,43 172,35 ±24,85 .039∗
TG (mg/dl) 146,30 ±67,64 85,30 ±41,55 .001∗
LDL-C (mg/dl) 111,34 ±29,59 98,00 ±29,56 .031∗
-C (mg/dl) 45,06 ±11,00 50,90 ±13,82 .077
∗Statistically signiﬁcant.
levels were signiﬁcantly higher in the male psoriatic patients
than in the male control subjects (P<. 05). There was no
statistically diﬀerence in HDL-C levels between the psoriatic
a n dt h ec o n t r o ls u b j e c t si nm a l eg r o u p( Table 4).
We did not observe any positive immune-ﬂuorescent
staininginthenonlesionalskinbiopsymaterialsofthepsori-
atic patients. Signiﬁcant positive immune-ﬂuorescent stain-
ing was observed in the psoriatic skin biopsy materials. The
dense cellular staining was observed in upper epidermis
(Figure 1).
4. DISCUSSION
Among the many studies on serum lipid values in psoriasis,
conﬂicting results have been reported. In studies on serum
TC levels in psoriatic patients, high [2, 9, 10], low [1, 11],
and normal [12, 13] values have all been reported. In our
study, we found signiﬁcantly higher levels of TC values in
the psoriatic patients (P<. 05). As for serum LDL-C lev-
els, high [2]o rn o r m a l[ 1, 10, 12] values have also been re-
ported in psoriasis. We found that LDL-C values in the pa-
tients with psoriasis were signiﬁcantly higher than the con-
trol group (P<. 05). Normal [9, 10, 13]a n dl o w[ 1, 2]s e ru m
levels of HDL-C have been detected. In our study HDL-C
levels in psoriatic patients were signiﬁcantly lower than the
control group (P<. 01).
The same controversy exists regarding serum TG levels,
high [1, 2], low [11], and normal [9, 10, 12] values have also
been reported in psoriasis. We found that TG values in the
psoriatic patients were signiﬁcantly higher than the control
group (P<. 001).
The variety of data presented may be due to the fact
that the patients included in statistical analyses suﬀer from
(a)
(b)
Figure 1: (a) Fluorescent microscopic view of the nonlesional skin
biopsy material of psoriatic patient. There is no ﬂuorescent stain-
ing. (b) Fluorescent microscopic view of the psoriatic skin biopsy
material of the same patient. There is positive ﬂuorescent staining
which is the accumulation areas of oxidized low-density lipoprotein
(X100).
diﬀerent forms of psoriasis such as erythroderma and they
undergo various treatments. Our patients had no erythro-
derma or generalized pustulosis. Furthermore they had not
taken any medical treatment.
Our results were strongly related to the gender of the pa-
tients. TC, TG, and LDL-C levels were signiﬁcantly higher in
the male psoriatic patients than in the male control subjects.
There was no statistically diﬀerence in the female groups.
Only for the females, HDL-C levels were lower in the pso-
riatic patients than in the control subjects. There was no dif-
ferenceinthemalegroupsforHDL-Clevels.Consideringthe
results of our research we would suggest analyzing the lipid
proﬁles separately in males and females.
The relationship between augmented LDL-C level and
psoriasis is unclear. However, ox-LDL may be more illumi-
native than native LDL. Native LDL is only taken up mod-
estlyby macrophages,whereasmodiﬁed LDLis rapidly taken
up via scavenger receptors [14]. The major modiﬁcation
of LDL particles in vivo is believed to be the oxidation of
both its lipid and protein components [15]. Oxidized or
modiﬁed LDLs are the main subjects of many inﬂammatory4 Mediators of Inﬂammation
conditions such as atherosclerosis. The oxidized LDL hy-
pothesis is discovered by Goldstein et al. [16] and modiﬁed
by Steinberg et al. [17]. The current oxidative modiﬁcation
or stress hypothesis of atherosclerosis predicts that LDL oxi-
dation is an early, essential event in atherosclerosis and that
ox-LDL does contribute to both initiation and progression
of atherosclerosis [18]. The oxidative modiﬁcation hypoth-
esis focuses on the concept that LDL in its native form is
not atherogenic. The presence of ox-LDL in atherosclerotic
lesions has been studied using antibodies that recognize spe-
ciﬁc epitopes on ox-LDL, which are not present in its native,
nonoxidized, form. These antibodies avidly stain atheroscle-
rotic lesions in humans with no demonstrable staining in
normal arteries [19].
A typical feature of atherosclerosis is the accumulation
of oxidatively modiﬁed LDLs within plaques. Also these
lipoproteins are considered to contribute to the inﬂamma-
torystateofatherosclerosisandtoplayakeyroleinitspatho-
genesis [20]. The cellular uptake of ox-LDL leads to the gen-
eration of reactive oxygen species (ROS) [21]. ROS are po-
tentiallyveryharmfulsubstances,becausetheycanreactwith
proteins,DNA,orlipids.Inotherwords,theaccumulationof
ox-LDL can be starter of oxidative stress.
The importance of this manuscript is to show the exis-
tence of ox-LDL in psoriatic skin. This study shows for the
ﬁrst time the accumulation of oxidized low-density lipopro-
tein in psoriatic skin lesions by direct immune-ﬂuorescent
method. Ox-LDL or anti-ox-LDL antibody levels can be
measured in blood samples or body ﬂuids by conventional
biochemical and immunological methods. Especially, the
level of anti-ox-LDL has been suggested to reﬂect the in vivo
oxidationofLDL.ThestudiesofVanizorKural[3]and¨ Orem
[7] have demonstrate the existence of these antibodies in
psoriasis. The level of anti-ox-LDL antibody was positively
correlated with TC and negatively correlated with HDL-C
in their studies. In our study, we detected accumulation of
ox-LDL in psoriatic skin. This accumulation is markedly in-
creased especially in upper epidermis. The upper-epidermal
cells had dens cellular staining with anti-ox-LDL antibodies.
Basal layer of epidermis was not stained. We did not observe
any positive immune-ﬂuorescent staining in the nonlesional
skin biopsy materials of the psoriatic patients. Leren et al.
have observed that tissue-cultered skin ﬁbroblasts from pso-
riatic patients have reduced LDL receptor activity [22]. Their
study has no diﬀerence in LDL receptor activity between in-
volved and uninvolved skin from our psoriasis patients. In
ourstudy,weonlyfocusedontheepidermallayerofinvolved
and uninvolved skin from psoriatic patients. We detected ac-
cumulationofox-LDLintheupperepidermisoftheinvolved
skin from the psoriatic patients. Ox-LDL can use native LDL
r e c e p t o r .H o w e v e r ,i th a sah i g h - a ﬃnity advantage than its
native form.
In conclusion, ox-LDL is an important marker of oxida-
tive stress and lipid peroxidation process. Importantly, ox-
LDL, by itself, may induce inﬂammation [23]. This capabil-
ity may directly aﬀect psoriatic epidermis and we believe that
the accumulation of ox-LDL in the psoriatic skin may have
an important role in pathogenesis of psoriasis.
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